Surfaxin approval will hinge on preclinical work

Shares of Discovery Labs (DSCO) shot up 10 percent this morning after the developer announced that it would only need to conduct new animal studies of its experimental therapy Surfaxin for respiratory illness in children rather than a new clinical trial. "Compared to the conduct of a PD clinical trial, a comprehensive preclinical program, if successful, presents an opportunity to significantly reduce the time and expense required to gain potential Surfaxin approval," the company said. Report